Malignancy in SARS-CoV2 infection

Version 4 2020-10-26, 08:32

Version 3 2020-10-26, 08:30

Version 2 2020-10-26, 08:13

Version 1 2020-07-17, 10:20

dataset

posted on 2020-10-26, 08:32 authored by Massimo Rugge, Manuel Zorzi, Stefano GuzzinatiStefano Guzzinati

Study population: all the residents in the Veneto Region who were consecutively tested for SARS-CoV-2 infection between February 22nd and April 1st, 2020.

Study variables:

· demographics (age, sex)

· history of malignant disease (prevalent diagnosis of malignant cancer, cancer site, interval between diagnosis of cancer and testing for SARS-CoV-2 infection)

· clinical outcomes of SARS-CoV-2 infection (admission to hospital; admission to Intensive Care Unit; death)